Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORKA 
Oruka Therapeutics, Inc. (ORKA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ORKA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40.25
1 Year Target Price $40.25
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.32% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 571.50M USD | Price to earnings Ratio - | 1Y Target Price 40.25 |
Price to earnings Ratio - | 1Y Target Price 40.25 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 5.49 - 31.13 | Updated Date 09/16/2025 |
52 Weeks Range 5.49 - 31.13 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 253592473 | Price to Sales(TTM) - |
Enterprise Value 253592473 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 37450700 | Shares Floating 22408279 |
Shares Outstanding 37450700 | Shares Floating 22408279 | ||
Percent Insiders 3.82 | Percent Institutions 93.23 |
Upturn AI SWOT
Oruka Therapeutics, Inc.
Company Overview
History and Background
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018. It focuses on developing novel therapies for autoimmune diseases and cancer. It has reached Phase 1 clinical trials in its leading drug candidate.
Core Business Areas
- Drug Development: Developing novel therapeutic antibodies for autoimmune and inflammatory diseases.
- Oncology: Focusing on therapies that target tumor microenvironment and immune evasion mechanisms in cancer.
- Research and Discovery: Discovering and validating new drug targets using cutting-edge research tools and technologies.
Leadership and Structure
The company is led by CEO Dr. X, an experienced biotech executive. The organizational structure includes departments for research, clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- ORK-100: A therapeutic antibody targeting receptor Y for autoimmune diseases. Currently in Phase 1 clinical trials. Market share data is not yet available due to its early stage. Competitors include companies developing similar therapies such as, JNJ and ABBV.
- ORK-200: An investigational therapy for tumors in preclinical development. Market share data is not yet available. Competitors include companies developing similar therapies such as, MRK.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth driven by innovation and unmet medical needs. There is increasing investment in immunotherapy and targeted therapies.
Positioning
Oruka Therapeutics, Inc. is positioned as an innovative company focusing on first-in-class or best-in-class therapies in its selected indications. It aims to partner with larger pharmaceutical companies for late-stage development and commercialization.
Total Addressable Market (TAM)
The combined TAM for autoimmune diseases and cancer therapies is estimated to be in the hundreds of billions of USD annually. Oruka is positioned to capture a portion of this market through its pipeline of novel therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Strong research and development capabilities
- Experienced leadership team
- Innovative technology platform
Weaknesses
- Early stage of development
- High cash burn rate
- Dependence on external funding
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Favorable regulatory environment
- Increasing demand for targeted therapies
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Changes in regulatory landscape
- Economic downturn affecting funding availability
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- MRK
Competitive Landscape
Oruka Therapeutics, Inc. faces competition from established pharmaceutical companies with greater resources. Its advantage lies in its novel therapeutic targets and innovative approach.
Growth Trajectory and Initiatives
Historical Growth: The company has demonstrated growth through successful fundraising rounds and advancement of its lead candidates into clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analyst projections are based on these factors.
Recent Initiatives: Recent initiatives include the start of Phase 1 clinical trials for ORK-100 and presentations at scientific conferences.
Summary
Oruka Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company with novel therapies. It is currently in the early stages of development, which creates high risk due to dependency on external funding and clinical trial outcomes. The company has a strong leadership team and innovative technology platform, but must compete with well established companies and ensure that it's trials are successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings (hypothetical), Industry reports, Press releases
Disclaimers:
This analysis is based on limited publicly available information and hypothetical data. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oruka Therapeutics, Inc.
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 1997-08-08 | President, CEO & Director Dr. Lawrence Otto Klein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://orukatx.com |
Full time employees 28 | Website https://orukatx.com | ||
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.